Doxofylline: Advancing and Empowering Equitable Asthma and COPD Management Beyond Tradition

Abstract

Doxofylline, a newer methylxanthine derivative, has garnered increasing attention for its distinct pharmacological properties and therapeutic advantages over traditional agents such as theophylline. This paper provides a comprehensive review of the pharmacological characteristics and clinical efficacy of doxofylline, elucidating why it represents a significant advancement in methylxanthine therapy. Moreover, attention is given to the economic considerations surrounding its utilization, particularly in low- and medium-income countries where access to healthcare resources is limited. The affordability, improved tolerability, and dosing convenience of doxofylline make it a promising candidate for addressing the substantial burden of asthma and COPD in resource-constrained settings.